Cancer Research

The rising cost of treating and caring for a growing number of cancer patients threatens economic development in low and middle income countries (LMICs), making prevention a key element of health care plans, according to a new commentary.

Authored by researchers from the International Agency for Research on Cancer (IARC), the American Cancer Society, and Imperial College of London, the commentary says in the absence of the implementation of prevention, LMICs will not have the resources to diagnose and treat all new cancer patients, and the economic burden will soon become unsustainable. The commentary appears in the Journal of the National Cancer Institute (JNCI).

Lung cancer screening programs that utilize standardized reporting and include cardiothoracic surgeons as part of a multidisciplinary team can successfully be adopted into clinical practice without an increase in surgical intervention for non-cancerous disease, according to an article in the October 2015 issue of The Annals of Thoracic Surgery.

Key points

  • Lung cancer screening programs can be safely and effectively adopted in clinical practice with low rates of surgical intervention for non-cancerous disease

  • Surgical intervention for a non-cancer diagnosis was rare, at 0.24%, which is comparable to the National Lung Screening Trial.

  • Patients with advanced gastrointestinal neuroendocrine tumors (NETs) have limited treatment options and there are few oncologists who are specialized in this relatively rare disease. But now results from a multi-center randomized international trial of an innovative treatment show a marked improvement in the length of time patients with mid-gut NETs live without the disease getting worse (progression-free survival, or PFS), researchers reported to the 2015 European Cancer Congress.

    High circulating levels of cardiovascular hormones/peptides in cancer patients have been linked to shorter survival, regardless of disease type and stage of progression in a new paper.

    These chemicals, known as biomarkers, are apparent in the absence of any clinical signs of heart disease or infection, and before the start of anti-cancer treatment, some of which is known to damage heart tissue, say the researchers.

    Levels of cardiovascular hormones/peptides have been used to monitor the severity and progression of heart tissue damage as a result of either chemotherapy or radiotherapy. But what has not been clear is whether the cancer itself may affect the levels of these chemicals.

    Western University researchers are working on a way to use artificial intelligence to predict a patient's response to two common chemotherapy medications used to treat breast cancer - paclitaxel and gemcitabine.

    Peter Rogan, PhD, and a team of researchers, including Stephanie Dorman, PhD, and Katherina Baranova, BMSc, at Western's Schulich School of Medicine&Dentistry, are hoping to one day remove the guesswork from breast cancer treatment with this technique.

    Based on personal genetic analysis of their tumours, patients with the same type of cancer can have different responses to the same medication. While some patients will respond well and go into remission, others will develop a resistance to the medication.

    Researchers have identified for the first time the triple mechanism that stops chromosome separation in response to situations that compromise the integrity of the genetic information. The loss of this response capacity is characteristic of cancerous cells.

    Cell proliferation requires the chromosomes to be copied (replicated) and distributed (segregated) to the two future daughter cells. Cells continually undergo spontaneous alterations (injuries) to the DNA that makes up the chromosomes, because of their aqueous (reactive) environment, for example. In response to DNA injuries, cells put a stop to the cell division cycle, in order to allow time for the injuries to be repaired and prevent the transmission of damaged, incompletely replicated chromosomes.

    Engineers have developed a new medical device aimed at improving diagnostic procedures for various cancers. The Tadpole Endoscope is like a micro-robot fish with a camera which is swallowed by the patient.

    It is different from existing wireless capsule endoscopes by addition of a soft tail that allows it to be guided around the stomach remotely by a doctor, allowing for more comprehensive imaging and accurate location of problems within the body.

    We want drugs to get better and we don’t want them to be just for the rich. Health care, in much of modern America, has become a right rather than a luxury so a country that is fine with overpaying for a phone is less inclined to have gaps in health care quality.

    People want Apple and Samsung to make money so the companies are motivated to create the next great phone. If Apple is the most highly-valued company in the U.S., they earned it and if you want their new iPhone 6s first, you pay the price, even if the new features are negligible.

    In its first clinical trial, an antibody therapy produced at least partial remissions in a third of patients with multiple myeloma who had exhausted multiple prior treatments, investigators at Dana-Farber Cancer Institute and other organizations have reported.

    The drug, daratumumab, proved generally safe in patients, even at the highest doses tested in the study. The results of the trial - a combined phase 1 and 2 study - strongly support testing of the drug in a larger group of patients in both phase 2 and 3 trials, the authors say.

    New research could potentially yield a new platform for cancer vaccines. Leveraging a biologically inspired sponge-like gel called "cryogel" as an injectable biomaterial, the vaccine delivers patient-specific tumor cells together with immune-stimulating biomolecules to enhance the body's attack againstcancer. The approach, a so-called "injectable cryogel whole-cell cancer vaccine."

    David Mooney, Ph.D., leads a Wyss Institute team developing a broad suite of novel cancer vaccines and immunotherapies.